Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study.
In Ah ChoiAkira SagawaEun Young LeeEun Bong LeeYeong-Wook SongPublished in: Journal of Korean medical science (2020)
Weight and the leptin-adiponectin ratio increased after tocilizumab treatment. Given that cardiovascular (CV) risk factors may deteriorate in patients with RA who receive tocilizumab, further studies are required to determine the effects of weight gain on CV outcomes in these patients.
Keyphrases
- weight gain
- rheumatoid arthritis
- body weight
- body mass index
- risk factors
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- end stage renal disease
- birth weight
- newly diagnosed
- disease activity
- ejection fraction
- chronic kidney disease
- metabolic syndrome
- insulin resistance
- peritoneal dialysis
- physical activity
- systemic lupus erythematosus
- interstitial lung disease
- adipose tissue
- systemic sclerosis